Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

<p>Abstract</p> <p>Background</p> <p>Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the...

Full description

Bibliographic Details
Main Authors: Galactéros Frédéric, Pham Kim PD, Bachir Dora, Habibi Anoosha, Sassi Hind, Paule Ines, Girard Pascal, Hulin Anne, Tod Michel
Format: Article
Language:English
Published: BMC 2011-05-01
Series:Orphanet Journal of Rare Diseases
Online Access:http://www.ojrd.com/content/6/1/30

Internet

http://www.ojrd.com/content/6/1/30

Similar Items